Literature DB >> 7727178

Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis.

S Ye1, G F Watts, S Mandalia, S E Humphries, A M Henney.   

Abstract

Stromelysin is a member of the family of metalloproteinases that degrade extracellular matrix. In situ hybridisation and histopathological studies suggest that stromelysin activity may be important in the connective tissue remodelling processes associated with atherogenesis and plaque rupture. Single strand conformation polymorphism analysis identified a common polymorphism in the stromelysin gene promoter located 1171 bp upstream from the start of transcription in which one allele has a run of six adenosines (6A) and another has five adenosines (5A). 72 men with coronary heart disease, were genotyped. They were participants in the St Thomas' Atherosclerosis Regression Study who were randomised to receive usual care (UC), dietary intervention (D), or diet plus cholestyramine (DC), with angiography at baseline and at 39 months. In these patients the frequency of the 5A allele was 0.49 (95% CI from 0.41 to 0.57) and was not significantly different from that in a sample of 354 healthy UK men. In the UC group, patients who were homozygous for the 6A allele showed greater progression of angiographic disease than those with other genotypes: the minimum absolute width of coronary segments decreased by 0.04 (SEM 0.10) mm for 5A5A, 0.20 (0.07) mm for 5A6A, and 0.67 (0.19) mm for 6A6A (P < 0.01). The findings were similar but slightly less significant for the change in mean absolute width of coronary segments (P < 0.05). No significant associations were seen in patients in the D or DC groups. In data pooled from the three treatment groups, the 6A6A genotype was significantly associated with greater progression of coronary atherosclerosis than other genotypes in patients with baseline percentage diameter stenosis less than 20% (P < 0.05), but not in those with baseline percentage diameter stenosis greater than or equal to 20%. These results provide the first evidence of a link between genetic variation in stromelysin and progression of coronary atherosclerosis and support the hypothesis that connective tissue remodeling mediated by metalloproteinases contribute to the pathogenesis of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7727178      PMCID: PMC483800          DOI: 10.1136/hrt.73.3.209

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  31 in total

1.  Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by dexamethasone.

Authors:  S M Frisch; H E Ruley
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Transcriptional regulation of human stromelysin.

Authors:  S Quinones; J Saus; Y Otani; E D Harris; M Kurkinen
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157

4.  Growth factors regulate transin gene expression by c-fos-dependent and c-fos-independent pathways.

Authors:  L D Kerr; J T Holt; L M Matrisian
Journal:  Science       Date:  1988-12-09       Impact factor: 47.728

Review 5.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

6.  Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death.

Authors:  M J Davies; J M Bland; J R Hangartner; A Angelini; A C Thomas
Journal:  Eur Heart J       Date:  1989-03       Impact factor: 29.983

7.  Studies of regression of advanced atherosclerosis in experimental animals and man.

Authors:  R W Wissler; D Vesselinovitch
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

8.  Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration.

Authors:  S E Humphries; A Lane; F R Green; J Cooper; G J Miller
Journal:  Arterioscler Thromb       Date:  1994-02

9.  Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?

Authors:  W C Little; M Constantinescu; R J Applegate; M A Kutcher; M T Burrows; F R Kahl; W P Santamore
Journal:  Circulation       Date:  1988-11       Impact factor: 29.690

10.  Angiographic evolution of coronary artery morphology in unstable angina.

Authors:  J A Ambrose; S L Winters; R R Arora; A Eng; A Riccio; R Gorlin; V Fuster
Journal:  J Am Coll Cardiol       Date:  1986-03       Impact factor: 24.094

View more
  57 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 2.  Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

5.  Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study.

Authors:  Richard Sherva; Charles E Ford; John H Eckfeldt; Barry R Davis; Eric Boerwinkle; Donna K Arnett
Journal:  Stroke       Date:  2010-12-23       Impact factor: 7.914

6.  Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease.

Authors:  Benjamin D Horne; Nicola J Camp; John F Carlquist; Joseph B Muhlestein; Matthew J Kolek; Zachary P Nicholas; Jeffrey L Anderson
Journal:  Am Heart J       Date:  2007-10       Impact factor: 4.749

7.  Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China.

Authors:  Yan Li; Dong-lan Sun; Ya-nan Duan; Xiao-juan Zhang; Na Wang; Rong-miao Zhou; Zhi-feng Chen; Shi-jie Wang
Journal:  Mol Biol Rep       Date:  2009-06-28       Impact factor: 2.316

Review 8.  Genetics of disc degeneration.

Authors:  Danny Chan; Youqiang Song; Pak Sham; Kenneth M C Cheung
Journal:  Eur Spine J       Date:  2006-07-04       Impact factor: 3.134

9.  Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease.

Authors:  Hyun Phil Shin; Joung Il Lee; Joo-Ho Jung; Sung-Vin Yim; Hyun Jeong Kim; Jae Myung Cha; Jong Beom Park; Kwang Ro Joo; Jae Seok Hwang; Byoung-Kuk Jang
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

10.  Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children.

Authors:  Young Mi Hong; Hyun-Seung Jin; In Sook Park; Soo-Jong Hong
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.